JPWO2023204259A1 - - Google Patents

Info

Publication number
JPWO2023204259A1
JPWO2023204259A1 JP2024505170A JP2024505170A JPWO2023204259A1 JP WO2023204259 A1 JPWO2023204259 A1 JP WO2023204259A1 JP 2024505170 A JP2024505170 A JP 2024505170A JP 2024505170 A JP2024505170 A JP 2024505170A JP WO2023204259 A1 JPWO2023204259 A1 JP WO2023204259A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024505170A
Other versions
JPWO2023204259A5 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2023204259A1 publication Critical patent/JPWO2023204259A1/ja
Publication of JPWO2023204259A5 publication Critical patent/JPWO2023204259A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024505170A 2022-04-20 2023-04-19 Pending JPWO2023204259A1 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022069320 2022-04-20
EP22207829 2022-11-16
PCT/JP2023/015683 WO2023204259A1 (ja) 2022-04-20 2023-04-19 がんの治療又は予防用医薬

Publications (2)

Publication Number Publication Date
JPWO2023204259A1 true JPWO2023204259A1 (ja) 2023-10-26
JPWO2023204259A5 JPWO2023204259A5 (ja) 2024-04-01

Family

ID=88419939

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024505170A Pending JPWO2023204259A1 (ja) 2022-04-20 2023-04-19

Country Status (3)

Country Link
JP (1) JPWO2023204259A1 (ja)
TW (1) TW202404586A (ja)
WO (1) WO2023204259A1 (ja)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR121078A1 (es) * 2020-01-22 2022-04-13 Chugai Pharmaceutical Co Ltd Derivados de arilamida con actividad antitumoral
US20230270730A1 (en) * 2020-07-22 2023-08-31 Chugai Seiyaku Kabushiki Kaisha Composition containing arylamide derivative
JPWO2022018875A1 (ja) * 2020-07-22 2022-01-27

Also Published As

Publication number Publication date
WO2023204259A1 (ja) 2023-10-26
TW202404586A (zh) 2024-02-01

Similar Documents

Publication Publication Date Title
BR102022026909A2 (ja)
BR102022023461A2 (ja)
BR102022017795A2 (ja)
BY13135U (ja)
BY13147U (ja)
CN307104317S (ja)
CN307098666S (ja)
CN307097636S (ja)
CN307095470S (ja)
CN307093705S (ja)
CN307093633S (ja)
CN307093556S (ja)
CN307086070S (ja)
CN307085181S (ja)
CN307079682S (ja)
CN307075789S (ja)
CN307073324S (ja)
CN307069568S (ja)
CN307054675S (ja)
CN307054563S (ja)
CN307053192S (ja)
CN307053027S (ja)
CN307051576S (ja)
CN307049068S (ja)
CN307046241S (ja)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240126

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402